PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE persons are required to respond to a collection of information unless it displays a valid OMB control number Application Number 10/567,699 Filing Date TRANSMITTAL February 3, 2006 First Named Inventor **FORM** Gianni Savi Art Unit Unknown Examiner Name Unknown (to be used for all correspondence after initial filing) Attorney Docket Number NOTAR-031US Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Drawing(s) Fee Transmittal Form **Appeal Communication to Board** Licensing-related Papers of Appeals and Interferences Fee Attached Appeal Communication to TC Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify **Terminal Disclaimer** below): **Extension of Time Request** - Form PTO/SB/08B (in duplicate) Request for Refund Express Abandonment Request - Prior Art (5 non patent literature) CD, Number of CD(s) Information Disclosure Statement Return postcard Landscape Table on CD Remarks Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name GARRED & BRUCKER Signature Printed name Kit M. Stetina Reg. No. Date 29,445 May 8, 2006 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Josephine I. Weissberger

Date

May 8, 2006

Signature

Typed or printed name



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Gianni Sava Laura Zorzin Dario Vojnovic)	
Serial No.:	Unknown)	Art Unit: Unknown
Filing Date:	Herewith)	Examiner: Unknown
For:	POLYSACCHARIDE DOUBLE- LAYER MICROCAPSULES AS CARRIERS FOR BIOLOGICALLY ACTIVE SUBSTANCE ORAL ADMINISTRATION)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. SECTION 1.97

Mail Stop Amendment Assistant Commissioner for Patents Post Office Box 1450 Alexandria, Virginia 22313-1450

Dear Sir/Madam:

Pursuant to 37 C.F.R. § 1.97, the following Supplemental Information Disclosure Statement is submitted as listed on form PTO/SB/08B enclosed herewith in duplicate. Copies of all disclosure documents are attached hereto for the Examiner's review.

No representation is made that the references disclosed herein legally constitute prior art, or that more relevant references are not available. The disclosure documents enclosed herewith and listed on the attached form PTO/SB/08B are printed in the English language and/or accompanied by an Abstract published in the English language.

The references listed herein, when taken alone or in combination, are not believed to disclose nor make obvious the invention as claimed in the subject application.

As this Supplemental Information Disclosure Statement is being submitted before the stipulated three months from the filing date of the application and/or before the mailing of a first Office Action, it is believed that no fee is required.

If a fee is required, please charge Account Number 19-4330.

Respectfully submitted,

Dated: May 8, 2006

By:

Customer No. 007663

Kit M. Stetina, Esq.

Registration No. 29,445

STETINA BRUNDA GARRED & BRUCKER

75 Enterprise, Suite 250 Aliso Viejo, CA 92656

(949) 855-1246

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Complete if Known				
Application Number	10/567.699			
Filing Date	February 2, 2006			
First Named Inventor	Gianni Sava			
Group Art Linit	Linknown			

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Unknown (use as many sheets as necessary) **Examiner Name** of Attorney Docket Number NOTAR-031US Sheet

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
		A. POLK, B. AMSDEN, K. DE YAO, T. PENG and M.F.A. GOOSEN; "Controlled Release of Albumin from Chitosan-Alginate Microcapsules", Journal of Pharmaceutical Sciences; Feb. 1994; pg. 178-185; Vol. 83, No. 2	
		G.W. VANDENBERG, C. DROLET, S.L. SCOTT and J. DE LA NOUE; "Factors Affecting Protein Release from Alginate-Chitosan Coacervate Microcapsules During Production and Gastric Intestinal Simulation"; Journal of Controlled Release; Mar. 2001; pg. 297-307	
		I.M. VAN DER LUBBEN, J.C. VERHOEF, G. BORCHARD and H.E. JUNGINGER; "Chitosan for Mucosal Vaccination"; www.aapspharmaceutica.com; Mar. 2006	
		L.J. SCHEP, I.G. TUCKER, G. YOUNG, R. LEDGERand A.G. BUTT; "Controlled Release Opportunities for Oral Peptide Delivery in Aquaculture"; Journal of Controlled Release; Sept. 1998; pg. 1-14	
		A.J. AINSWORTH, C.D. RICE and L. XUE; "Immune Responses of Channel Catfish, Lctalurus Punctatus "; CSA Illumina; Mar. 2006	
			T
			Ī
		·	
			_

1	Examiner	Date
l	Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents,